Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt N/A
SNY's Cash to Debt is ranked higher than
83% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. SNY: N/A )
Ranked among companies with meaningful Cash to Debt only.
SNY' s 10-Year Cash to Debt Range
Min: 0.14  Med: 9999.00 Max: N/A
Current: N/A
Interest Coverage 10.15
SNY's Interest Coverage is ranked lower than
79% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2065.49 vs. SNY: 10.15 )
Ranked among companies with meaningful Interest Coverage only.
SNY' s 10-Year Interest Coverage Range
Min: 7.88  Med: 12.12 Max: 19.65
Current: 10.15
7.88
19.65
WACC vs ROIC
8.92%
15.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 17.44
SNY's Operating margin (%) is ranked higher than
78% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. SNY: 17.44 )
Ranked among companies with meaningful Operating margin (%) only.
SNY' s 10-Year Operating margin (%) Range
Min: 15.25  Med: 18.52 Max: 38.21
Current: 17.44
15.25
38.21
Net-margin (%) 12.34
SNY's Net-margin (%) is ranked higher than
73% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. SNY: 12.34 )
Ranked among companies with meaningful Net-margin (%) only.
SNY' s 10-Year Net-margin (%) Range
Min: 7.92  Med: 14.85 Max: 25.8
Current: 12.34
7.92
25.8
ROE (%) 15.78
SNY's ROE (%) is ranked higher than
75% of the 685 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.19 vs. SNY: 15.78 )
Ranked among companies with meaningful ROE (%) only.
SNY' s 10-Year ROE (%) Range
Min: 5.18  Med: 10.33 Max: 33.55
Current: 15.78
5.18
33.55
ROA (%) 9.14
SNY's ROA (%) is ranked higher than
73% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. SNY: 9.14 )
Ranked among companies with meaningful ROA (%) only.
SNY' s 10-Year ROA (%) Range
Min: 2.62  Med: 6.07 Max: 21.59
Current: 9.14
2.62
21.59
ROC (Joel Greenblatt) (%) 79.01
SNY's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.97 vs. SNY: 79.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 31.89  Med: 49.01 Max: 145.55
Current: 79.01
31.89
145.55
Revenue Growth (3Y)(%) -1.00
SNY's Revenue Growth (3Y)(%) is ranked lower than
71% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. SNY: -1.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SNY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1  Med: 6.30 Max: 27.4
Current: -1
-1
27.4
EBITDA Growth (3Y)(%) -4.40
SNY's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 483 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. SNY: -4.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SNY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -4.4  Med: 5.70 Max: 35.7
Current: -4.4
-4.4
35.7
EPS Growth (3Y)(%) -8.20
SNY's EPS Growth (3Y)(%) is ranked lower than
66% of the 451 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. SNY: -8.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SNY' s 10-Year EPS Growth (3Y)(%) Range
Min: -12.8  Med: 3.40 Max: 41.2
Current: -8.2
-12.8
41.2
» SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SNY Guru Trades in Q3 2014

Manning & Napier Advisors, Inc 5,024,798 sh (+69.69%)
PRIMECAP Management 3,891,356 sh (+29.21%)
Bill Nygren 5,670,000 sh (+14.55%)
Sarah Ketterer 593,929 sh (+4.58%)
Charles Brandes 2,248,902 sh (+3.05%)
Mario Gabelli 4,580 sh (+1.78%)
John Buckingham 20,665 sh (+1.58%)
HOTCHKIS & WILEY 9,895,521 sh (+1.26%)
Ken Fisher 13,145,647 sh (+0.51%)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Scott Black 178,410 sh (-0.32%)
Dodge & Cox 43,267,004 sh (-0.65%)
James Barrow 28,293,723 sh (-0.82%)
NWQ Managers 2,409,040 sh (-7.43%)
Third Avenue Management 12,306 sh (-8.18%)
First Eagle Investment 34,157 sh (-94.39%)
» More
Q4 2014

SNY Guru Trades in Q4 2014

David Dreman 1,102 sh (New)
Steven Cohen 1,050,000 sh (New)
NWQ Managers 2,941,923 sh (+22.12%)
HOTCHKIS & WILEY 11,692,693 sh (+18.16%)
Charles Brandes 2,571,795 sh (+14.36%)
Mario Gabelli 5,195 sh (+13.43%)
PRIMECAP Management 4,287,207 sh (+10.17%)
James Barrow 30,804,459 sh (+8.87%)
John Buckingham 22,394 sh (+8.37%)
Manning & Napier Advisors, Inc 5,433,472 sh (+8.13%)
Murray Stahl 26,295 sh (+1.13%)
Dodge & Cox 43,272,800 sh (+0.01%)
First Eagle Investment 34,157 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Ken Fisher 13,085,033 sh (-0.46%)
Scott Black 176,460 sh (-1.09%)
Third Avenue Management 10,704 sh (-13.02%)
Sarah Ketterer 506,796 sh (-14.67%)
» More
Q1 2015

SNY Guru Trades in Q1 2015

Paul Tudor Jones 7,598 sh (New)
NWQ Managers 3,927,517 sh (+33.50%)
John Buckingham 24,608 sh (+9.89%)
HOTCHKIS & WILEY 11,782,180 sh (+0.77%)
Charles Brandes 2,573,969 sh (+0.08%)
Bill Nygren 5,670,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
David Dreman 1,102 sh (unchged)
First Eagle Investment Sold Out
Steven Cohen Sold Out
Third Avenue Management Sold Out
Ken Fisher 13,058,095 sh (-0.21%)
Murray Stahl 26,185 sh (-0.42%)
Scott Black 175,625 sh (-0.47%)
Dodge & Cox 43,034,073 sh (-0.55%)
James Barrow 30,225,221 sh (-1.88%)
Sarah Ketterer 477,367 sh (-5.81%)
PRIMECAP Management 3,972,907 sh (-7.33%)
Mario Gabelli 4,700 sh (-9.53%)
Manning & Napier Advisors, Inc 2,499,440 sh (-54.00%)
» More
Q2 2015

SNY Guru Trades in Q2 2015

Manning & Napier Advisors, Inc 2,879,307 sh (+15.20%)
Ken Fisher 13,246,593 sh (+1.44%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Sanofi

Bill Nygren Comments on Sanofi - Apr 08, 2014

Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 30.07
SNY's P/E(ttm) is ranked higher than
58% of the 472 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.90 vs. SNY: 30.07 )
Ranked among companies with meaningful P/E(ttm) only.
SNY' s 10-Year P/E(ttm) Range
Min: 9.64  Med: 20.01 Max: 38.97
Current: 30.07
9.64
38.97
Forward P/E 17.18
SNY's Forward P/E is ranked higher than
68% of the 233 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.27 vs. SNY: 17.18 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.30
SNY's PE(NRI) is ranked higher than
58% of the 472 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.00 vs. SNY: 30.30 )
Ranked among companies with meaningful PE(NRI) only.
SNY' s 10-Year PE(NRI) Range
Min: 9.82  Med: 20.07 Max: 39.2
Current: 30.3
9.82
39.2
P/B 2.28
SNY's P/B is ranked higher than
67% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. SNY: 2.28 )
Ranked among companies with meaningful P/B only.
SNY' s 10-Year P/B Range
Min: 1.11  Med: 1.70 Max: 2.38
Current: 2.28
1.11
2.38
P/S 3.71
SNY's P/S is ranked lower than
53% of the 649 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.43 vs. SNY: 3.71 )
Ranked among companies with meaningful P/S only.
SNY' s 10-Year P/S Range
Min: 1.77  Med: 2.85 Max: 5.18
Current: 3.71
1.77
5.18
PFCF 129.83
SNY's PFCF is ranked lower than
79% of the 275 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.38 vs. SNY: 129.83 )
Ranked among companies with meaningful PFCF only.
SNY' s 10-Year PFCF Range
Min: 15.02  Med: 34.41 Max: 132.08
Current: 129.83
15.02
132.08
EV-to-EBIT 20.76
SNY's EV-to-EBIT is ranked higher than
57% of the 486 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.52 vs. SNY: 20.76 )
Ranked among companies with meaningful EV-to-EBIT only.
SNY' s 10-Year EV-to-EBIT Range
Min: 10.5  Med: 20.40 Max: 204.2
Current: 20.76
10.5
204.2
Shiller P/E 25.39
SNY's Shiller P/E is ranked higher than
67% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.83 vs. SNY: 25.39 )
Ranked among companies with meaningful Shiller P/E only.
SNY' s 10-Year Shiller P/E Range
Min: 11.35  Med: 16.89 Max: 25.8
Current: 25.39
11.35
25.8
Days Inventory 156.14
SNY's Days Inventory is ranked lower than
69% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.49 vs. SNY: 156.14 )
Ranked among companies with meaningful Days Inventory only.
SNY' s 10-Year Days Inventory Range
Min: 155.87  Med: 189.97 Max: 224.59
Current: 156.14
155.87
224.59
Days Sales Outstanding 74.40
SNY's Days Sales Outstanding is ranked lower than
51% of the 592 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.86 vs. SNY: 74.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
SNY' s 10-Year Days Sales Outstanding Range
Min: 61.29  Med: 74.50 Max: 103.32
Current: 74.4
61.29
103.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.03
SNY's Dividend Yield is ranked higher than
85% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. SNY: 3.03 )
Ranked among companies with meaningful Dividend Yield only.
SNY' s 10-Year Dividend Yield Range
Min: 1.41  Med: 3.67 Max: 5.46
Current: 3.03
1.41
5.46
Dividend Payout 0.85
SNY's Dividend Payout is ranked lower than
86% of the 393 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. SNY: 0.85 )
Ranked among companies with meaningful Dividend Payout only.
SNY' s 10-Year Dividend Payout Range
Min: 0.39  Med: 2.32 Max: 8.15
Current: 0.85
0.39
8.15
Dividend growth (3y) 3.80
SNY's Dividend growth (3y) is ranked lower than
59% of the 253 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. SNY: 3.80 )
Ranked among companies with meaningful Dividend growth (3y) only.
SNY' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 6.50 Max: 29.6
Current: 3.8
0
29.6
Yield on cost (5-Year) 3.84
SNY's Yield on cost (5-Year) is ranked higher than
84% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. SNY: 3.84 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SNY' s 10-Year Yield on cost (5-Year) Range
Min: 1.8  Med: 4.70 Max: 6.97
Current: 3.84
1.8
6.97
Share Buyback Rate -0.10
SNY's Share Buyback Rate is ranked higher than
79% of the 463 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -3.00 vs. SNY: -0.10 )
Ranked among companies with meaningful Share Buyback Rate only.
SNY' s 10-Year Share Buyback Rate Range
Min: 1.3  Med: -0.40 Max: -24.6
Current: -0.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 54.54
SNY's Price/Tangible Book is ranked lower than
98% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.32 vs. SNY: 54.54 )
Ranked among companies with meaningful Price/Tangible Book only.
SNY' s 10-Year Price/Tangible Book Range
Min: 6.48  Med: 11.69 Max: 2093.5
Current: 54.54
6.48
2093.5
Price/Projected FCF 6.07
SNY's Price/Projected FCF is ranked lower than
69% of the 321 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. SNY: 6.07 )
Ranked among companies with meaningful Price/Projected FCF only.
SNY' s 10-Year Price/Projected FCF Range
Min: 0.94  Med: 2.26 Max: 20.48
Current: 6.07
0.94
20.48
Price/Median PS Value 1.31
SNY's Price/Median PS Value is ranked higher than
55% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. SNY: 1.31 )
Ranked among companies with meaningful Price/Median PS Value only.
SNY' s 10-Year Price/Median PS Value Range
Min: 0.64  Med: 1.05 Max: 8.62
Current: 1.31
0.64
8.62
Earnings Yield (Greenblatt) (%) 4.83
SNY's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. SNY: 4.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SNY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.5  Med: 4.90 Max: 9.5
Current: 4.83
0.5
9.5
Forward Rate of Return (Yacktman) (%) -3.66
SNY's Forward Rate of Return (Yacktman) (%) is ranked lower than
71% of the 308 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.88 vs. SNY: -3.66 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SNY' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -4.1  Med: 20.60 Max: 48.4
Current: -3.66
-4.1
48.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:0O59.UK, SAN.France, SANF.Italy, SNW.Germany, SNYN.Mexico, SAN.Switzerland, SANNV.France, SNYNF.USA, SNW2.Germany,
Sanofi was incorporated under the laws of France on April 28,1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
» More Articles for SNY

Headlines

Articles On GuruFocus.com
Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
Amgen’s Cholesterol Fighting Drug Receives EU Approval May 26 2015 
Dodge & Cox Stock Fund First Quarter 2015 Commentary Apr 24 2015 
Mt Stocks Apr 19 2015 
Scottrade Mar 22 2015 
Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
Oh là là! Looking for Dividend Yield? Explore France Feb 27 2015 
FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
Dodge & Cox 2014 Equity Year in Review Feb 19 2015 

More From Other Websites
Sanofi paying up to $300M for rare thyroid cancer drug Jul 27 2015
Sanofi paying up to $300M for rare thyroid cancer drug Jul 27 2015
Why Regeneron's Approval is Bad News For Esperion Therapeutics Jul 27 2015
New England Journal of Medicine Publishes New Analyses Confirming that Sanofi Pasteur's Vaccine... Jul 27 2015
Have Analysts Fully Priced in Praluent to Regeneron? Jul 27 2015
AZN sells off non-core drugs Jul 27 2015
2:48 am Sanofi-Aventis' Genzyme acquires Caprelsa from AstraZeneca (Jul 27 2015
Sanofi: Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy... Jul 27 2015
Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa®... Jul 27 2015
Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK Jul 24 2015
Regeneron Cholesterol Fighter Wins FDA OK, With Conditions Jul 24 2015
Regeneron and Sanofi Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9... Jul 24 2015
Sanofi and Regeneron Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9... Jul 24 2015
Sanofi and Regeneron Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9... Jul 24 2015
Regeneron and Sanofi Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9... Jul 24 2015
Sanofi Cholesterol Drug Approved in U.S. for Some Patients Jul 24 2015
Sanofi and Regeneron Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the... Jul 24 2015
Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the... Jul 24 2015
The Future Of MannKind Jul 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK